MEI Pharma, Inc.
MEIPNASDAQHealthcare
$3.07
+$0.29(+10.43%)
Market Cap$20452012
P/E Ratio—
52W High$9
52W Low$1.46
MEI Pharma, Inc. (MEIP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MEIP · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 19, 2026EPS Actual
-$0.82
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 19, 2026
After Market Close
🔥 4-Quarter EPS Beat Streak
MEIP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 19, 2026 | — | -$0.82 | — | — | — | — |
| — Q4 FY2025 | Nov 10, 2025 | — | -$0.12 | — | — | — | — |
| — Q3 FY2025 | Sep 18, 2025 | — | -$1.13 | — | $0.00B | — | — |
| — Q2 FY2025 | May 13, 2025 | — | -$0.39 | — | — | — | — |
| ▲ Q1 FY2025 | Feb 12, 2025 | -$2.20 | -$0.48 | +78.2% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$1.70 | -$1.20 | +29.4% | — | — | — |
| ▲ Q3 FY2024 | Sep 19, 2024 | -$1.48 | -$1.13 | +23.6% | — | — | — |
| — Q2 FY2024 | May 9, 2024 | -$1.38 | -$1.37 | +0.7% | — | $0.00B | — |
Q1 FY2026
Feb 19, 2026
EPS Actual
-$0.82
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 10, 2025
EPS Actual
-$0.12
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Sep 18, 2025
EPS Actual
-$1.13
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
May 13, 2025
EPS Actual
-$0.39
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Feb 12, 2025Beat
EPS Actual
-$0.48
EPS Est.
-$2.20
EPS Surpr.
+78.2%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$1.20
EPS Est.
-$1.70
EPS Surpr.
+29.4%
Revenue
—
Q3 FY2024
Sep 19, 2024Beat
EPS Actual
-$1.13
EPS Est.
-$1.48
EPS Surpr.
+23.6%
Revenue
—
Q2 FY2024
May 9, 2024
EPS Actual
-$1.37
EPS Est.
-$1.38
EPS Surpr.
+0.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $-2.20 | $-2.20 | $-2.20 | 1 |
| Q3 FY2024 | $-1.70 | $-1.70 | $-1.70 | 1 |
| Q2 FY2024 | $-1.46 | $-1.41 | $-1.37 | 2 |
| Q1 FY2024 | $-1.66 | $-1.49 | $-1.31 | 2 |
| Q4 FY2023 | $-1.41 | $-1.41 | $-1.41 | 1 |
| Q3 FY2023 | $-1.79 | $-1.79 | $-1.79 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 18 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 19, 2026 | — | $2.60 | — | — |
| — Q4 FY2025 | Nov 10, 2025 | — | $2.60 | — | — |
| — Q3 FY2025 | Sep 18, 2025 | — | $2.61 | $2.71 | +3.83% |
| — Q2 FY2025 | May 13, 2025 | — | $2.09 | $2.09 | +0.00% |
| ▲ Q1 FY2025 | Feb 12, 2025 | +78.2% | $2.71 | $2.66 | -1.85% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +29.4% | $3.13 | $3.14 | +0.32% |
| ▲ Q3 FY2024 | Sep 19, 2024 | +23.6% | $3.04 | $3.14 | +3.29% |
| ▲ Q2 FY2024 | May 9, 2024 | +0.7% | $3.16 | $3.07 | -2.85% |
Q1 FY2026—
Report Date
Feb 19, 2026
EPS Beat/Miss
—
Price Before
$2.60
Price After
—
Q4 FY2025—
Report Date
Nov 10, 2025
EPS Beat/Miss
—
Price Before
$2.60
Price After
—
Q3 FY2025+3.83%
Report Date
Sep 18, 2025
EPS Beat/Miss
—
Price Before
$2.61
Price After
$2.71
Q2 FY2025+0.00%
Report Date
May 13, 2025
EPS Beat/Miss
—
Price Before
$2.09
Price After
$2.09
Q1 FY2025-1.85%
Report Date
Feb 12, 2025
EPS Beat/Miss
+78.2%
Price Before
$2.71
Price After
$2.66
Q4 FY2024+0.32%
Report Date
Nov 12, 2024
EPS Beat/Miss
+29.4%
Price Before
$3.13
Price After
$3.14
Q3 FY2024+3.29%
Report Date
Sep 19, 2024
EPS Beat/Miss
+23.6%
Price Before
$3.04
Price After
$3.14
Q2 FY2024-2.85%
Report Date
May 9, 2024
EPS Beat/Miss
+0.7%
Price Before
$3.16
Price After
$3.07
Avg Beat Reaction-0.27%
Beat Rate4 / 8 quarters
Largest Move+3.83% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MEIP ends December
MEI Pharma, Inc. (MEIP) most recently reported earnings on February 19, 2026 for Q1 FY2026, posting EPS of $-0.82 (in line with the analyst consensus of —). MEIP has beaten EPS estimates for 4 consecutive quarters. The next MEIP earnings date is expected around September 1, 2026.
Each quarter, investors track MEIP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MEIP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MEIP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MEIP earnings · 4 questionsMEI Pharma, Inc.'s next earnings report is expected around September 1, 2026. MEIP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MEIP historically reports after market close (AMC).
MEIP earnings datewhen is MEIP earningsMEIP next earnings datewhen does MEIP report earningsMEIP earnings calendar
▸ Source: FMP · MEI Pharma, Inc. SEC filings · US GAAP · MEI Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026